Nicolas Penel

2001–2025 年に発表

164
論文数
20,272
被引用数
77
h 指数
160
i10 指数

被引用数

Nicolas Penel の年別被引用数1996 年: 被引用 2 件2004 年: 被引用 2 件2005 年: 被引用 1 件2006 年: 被引用 1 件2007 年: 被引用 5 件2008 年: 被引用 6 件2009 年: 被引用 2 件2010 年: 被引用 18 件2011 年: 被引用 14 件2012 年: 被引用 27 件2013 年: 被引用 40 件2014 年: 被引用 68 件2015 年: 被引用 67 件2016 年: 被引用 79 件2017 年: 被引用 100 件2018 年: 被引用 89 件2019 年: 被引用 407 件2020 年: 被引用 864 件2021 年: 被引用 1,040 件2022 年: 被引用 900 件2023 年: 被引用 713 件2024 年: 被引用 1,222 件2025 年: 被引用 589 件2026 年: 被引用 9 件1997〜2003 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,844 件、この内訳の 20.8%中国: 引用元論文 951 件、この内訳の 10.8%イタリア: 引用元論文 695 件、この内訳の 7.9%フランス: 引用元論文 663 件、この内訳の 7.5%イギリス: 引用元論文 514 件、この内訳の 5.8%ドイツ: 引用元論文 473 件、この内訳の 5.3%スペイン: 引用元論文 351 件、この内訳の 4%オランダ: 引用元論文 317 件、この内訳の 3.6%日本: 引用元論文 316 件、この内訳の 3.6%カナダ: 引用元論文 271 件、この内訳の 3.1%スイス: 引用元論文 194 件、この内訳の 2.2%オーストラリア: 引用元論文 181 件、この内訳の 2%
0%20.8%その他 23.4%

分野

  • Medicine83%
  • Biochemistry, Genetics and Molecular Biology11.4%
  • Immunology and Microbiology3.1%
  • Neuroscience0.4%
  • Health Professions0.4%
  • Engineering0.4%
  • その他1.3%

トピック

  • Sarcoma Diagnosis and Treatment8.4%
  • Cancer Immunotherapy and Biomarkers7.7%
  • Cancer Genomics and Diagnostics3%
  • Vascular Tumors and Angiosarcomas2.6%
  • Pancreatic and Hepatic Oncology Research2.4%
  • Immunotherapy and Immune Responses2.4%
  • その他73.5%

共著者

全論文

検索で開く
  1. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

    著者: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 被引用: 2,963

  2. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study

    著者: , , , , , , , , , , , , , , , , - Annals of Oncology 2022 被引用: 445

  3. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort

    著者: , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2022 被引用: 263

  4. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alison Y. Zhang, Hans Prenen, Jean‐Charles Goeminne, Jean‐Pascal Machiels, Sylvie Rottey, Marcelo Corassa, Graziela Zibetti Dal Molin, Katsuki Arima Tiscoski, Denis L. Jardim, Milena Perez Mak, Wei Fu, Herui Yao, Jing Huang, Haiping Jiang, Jing Huang, Baoshi Chen, Dong Yan, Yu Yang, Yohann Loriot, Christophe Le Tourneau, Nicolas Penel, Sébastien Salas, Jean‐Yves Blay, Pierre-Emmanuel Brachet, Xavier Durando, Sheik Emambux, Alain Ravaud, Gunnar Folprecht, Dirk Arnold, Martin Schüler, Marit Ahrens, Alexander Golf, Georg Martin Haag, Florian Lordick, Alexander Desuki, Marina Elena Cazzaniga, Fortunato Ciardiello, Michèle Milella, Takafumi Koyama, Yoshiki Hirooka, Wataru Okamoto, Kenjiro Aogi, Yasutoshi Kuboki, Jung-Yun Lee, Sung‐Bae Kim, Myung‐Ju Ahn, Jong Hee Chang, Yongman Kim, Do‐Hyun Nam, Jaesung Park, Iwona Ługowska, Luis Paz‐Ares, Víctor Moreno, Andrés Cervantes, Mariona Calvo, Alejandro Falcón, Antonio González, Josep Tabernero, A. Martinez Bueno, Javier García-Corbacho, Federico Longo, Chia‐Jui Yen, Jen‐Shi Chen, Ming‐Feng Hou, Yee Chao, Kun‐Ming Rau, Tai‐Jan Chiu, Yin‐Hsun Feng, Chih‐Hung Hsu, Wen‐Tsung Huang ほか 33 名 - The Lancet Oncology 2023 被引用: 200

  5. Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas

    著者: , , , , , , , , , , , , , , - JAMA Oncology 2017 被引用: 394

  6. Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

    著者: , , , , , , , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2019 被引用: 438

  7. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2019 被引用: 286

  8. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 被引用: 322

  9. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Valérie Lebrun-Ly, Elsa Kalbacher, Florence Duffaud, Corinne Delcambre, Emmanuelle Bompas, Olivier Collard, Nicolás Isambert, Cécile Guillemet, P Soulié, María Rios, Esma Saâda-Bouzid - The Lancet Oncology 2022 被引用: 125

  10. Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philippe Rochaix, Anne Demuret, Jean‐Pierre Ghnassia, Lénaïg Mescam, Nicolas Macagno, Isabelle Birtwisle‐Peyrottes, Christophe Delfour, Émilie Angot, Isabelle Pommepuy, Dominique Ranchère, Claire Chemin-Airiau, Myriam Jean‐Denis, Yohan Fayet, Jean-Baptiste Courrèges, Nouria Mesli, Juliane Berchoud, Maud Toulmonde, Antoîne Italiano, Axel Le Cesne, Nicolas Penel, Françoise Ducimetière, F. Gouin, Jean‐Michel Coindre, Jean‐Yves Blay, on behalf of the NetSarc/RePPS/ResSos and French Sarcoma Group- Groupe d’Etude des Tumeurs Osseuses (GSF-GETO) networks - PLoS ONE 2021 被引用: 263

  11. First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration

    著者: , , , , , , , , , , , , , , , , , - Annals of Oncology 2024 被引用: 96

  12. Surgery in reference centers improves survival of sarcoma patients: a nationwide study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Emmanuelle Bompas, Christine Chevreau, Florence Duffaud, María Rios, Christophe Perrin, Nelly Firmin, François Bertucci, C. Le Péchoux, François Le Loarer, Olivier Collard, Marie Karanian, Mehdi Brahmi, Armelle Dufresne, Aurélien Dupré, Françoise Ducimetière, Antoine Giraud, David Pérol, Maud Toulmonde, Isabelle Ray‐Coquard, Antoîne Italiano, Axel Le Cesne, Nicolas Penel, Sylvie Bonvalot - Annals of Oncology 2019 被引用: 332

  13. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

    著者: , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2019 被引用: 275

  14. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

    著者: , , , , , , , , , , , , , , - The Lancet Oncology 2012 被引用: 563

  15. Improved survival using specialized multidisciplinary board in sarcoma patients

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2017 被引用: 362

  16. FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 94

  17. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2018 被引用: 316

  18. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 被引用: 88

  19. Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

    著者: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2008 被引用: 693

  20. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alex J. Lazar, Robert G. Maki, Tim Mathes, Christina Messiou, Fariba Navid, Yoshihiro Nishida, Elena Palassini, Nicolas Penel, Robert Pollock, Dawid Pieper, Marlene Portnoy, Chandrajit P. Raut, Evelyne Roets, Sergio Sandrucci, Marta Sbaraglia, Silvia Stacchiotti, Katherine A. Thornton, Winette van der Graaf, Kim van der Zande, Winan J. van Houdt, Víctor M. Villalobos, Andrew J. Wagner, Eva Wardelmann, Markus Wartenberg, Sarah Watson, Aaron R. Weiss, Nikolaos Zafiropoulos - European Journal of Cancer 2020 被引用: 478

  21. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort

    著者: , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2020 被引用: 82

  22. A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)

    著者: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2019 被引用: 247

  23. Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study

    著者: , , , , , , , , , , , , , , , - European Journal of Cancer 2019 被引用: 167

  24. AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , François Ghiringhelli, Nicolas Penel, Hans Prenen, Sanne Glad, Chen-Hua Chuang, Kiana Keyvanjah, Danielle M. Townsley, John R. Butler, Matthew P. Bourbeau, Sean Caenepeel, Paul E. Hughes - Cancer Discovery 2024 被引用: 70